Table 2 : The sensitivity and specificity of ANXA2 and/or AFP levels
in early and late hepatocellular carcinoma patient groups.
| Parameter | Group | ANXA2 % | AFP % | Both % |
| Sensitivity | Early HCC | 79.34% | 67.78% | 80.79% |
| Late HCC | 84.32 | 73.71% | 94.32% | |
| Specificity | Early HCC | 85.56 | 59.85% | 68.43% |
| Late HCC | 92.34 | 68.43% | 79.30% | |